{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:51:13Z","timestamp":1762249873638,"version":"3.40.5"},"reference-count":31,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA048417","UG3DA048387"],"award-info":[{"award-number":["R01DA048417","UG3DA048387"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["AQ\u20100039"],"award-info":[{"award-number":["AQ\u20100039"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Exper Analysis Behavior"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Opioid overdose and opioid use disorder continue to be significant public health challenges despite the availability of effective medications and significant efforts at all levels of society. The emergence of highly potent and efficacious opioids such as fentanyl and its derivatives over the last decade has only exacerbated what was already a substantial problem. Behavioral pharmacology research has proven invaluable for understanding the effects of drugs as well as developing and evaluating pharmacotherapies for disorders involving the central nervous system, including substance abuse disorders. This paper describes a program of research characterizing a potent, selective, and long\u2010lasting mu opioid receptor antagonist, methocinnamox, and evaluating its potential for treating opioid overdose and opioid use disorder. Studies in rodents and nonhuman primates demonstrate that methocinnamox prevents and reverses opioid\u2010induced ventilatory depression and selectively blocks opioid self\u2010administration. This work, taken together with rigorous in vitro and ex vivo studies investigating methocinnamox neuropharmacology, lays a solid foundation for the therapeutic utility of this potentially life\u2010saving medication. Moreover, these studies demonstrate how rigorous behavioral pharmacological studies can be integrated in a broader drug discovery and development research program.<\/jats:p>","DOI":"10.1002\/jeab.831","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T04:17:19Z","timestamp":1676002639000},"page":"392-406","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Behavioral pharmacology of methocinnamox: A potential new treatment for opioid overdose and opioid use disorder"],"prefix":"10.1002","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0958-5397","authenticated-orcid":false,"given":"David R.","family":"Maguire","sequence":"first","affiliation":[{"name":"Department of Pharmacology University of Texas Health Science Center at San Antonio  TX United States"},{"name":"Addiction Research, Treatment, and Training Center of Excellence University of Texas Health Science Center at San Antonio  TX United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles P.","family":"France","sequence":"additional","affiliation":[{"name":"Department of Pharmacology University of Texas Health Science Center at San Antonio  TX United States"},{"name":"Addiction Research, Treatment, and Training Center of Excellence University of Texas Health Science Center at San Antonio  TX United States"},{"name":"Department of Psychiatry University of Texas Health Science Center at San Antonio  TX United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"issue":"3","key":"e_1_2_10_2_1","first-page":"1027","article-title":"Assessment of relative intrinsic activity of mu\u2010opioid analgesics in vivo by using beta\u2010funaltrexamine","volume":"255","author":"Adams J. U.","year":"1990","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"volume-title":"Provisional drug overdose death counts","year":"2023","author":"Ahmad F. B.","key":"e_1_2_10_3_1"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.11.002"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15580"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33078-2"},{"issue":"3","key":"e_1_2_10_7_1","first-page":"933","article-title":"Methocinnamox is a potent, long\u2010lasting, and selective antagonist of morphine\u2010mediated antinociception in the mouse: Comparison with clocinnamox, beta\u2010funaltrexamine, and beta\u2010chlornaltrexamine","volume":"294","author":"Broadbear J. H.","year":"2000","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2098"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2019_265"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.253286"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.260331"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0014-2999(00)00176-x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.120.000387"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000166"},{"key":"e_1_2_10_15_1","first-page":"164","volume-title":"The neuropharmacological basis of reward","author":"Katz J. L.","year":"1989"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.301.2.698"},{"key":"e_1_2_10_17_1","first-page":"136","article-title":"New 14\u2010aminomorphinones and codeinones","volume":"90","author":"Lewis J.","year":"1988","journal-title":"NIDA Research Monograph"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0169-328x(97)00353-7"},{"volume-title":"NAM Perspectives","author":"Madras, B. K., Ahmad, N. J., Wen, J., Sharfstein, J. S., & the Prevention, Treatment, and Recovery Working Group of the Action Collaborative on Countering the U.S. Opioid Epidemic","key":"e_1_2_10_19_1"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.122.001233"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-0698-8"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.252353"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0376-8716(98)00082-9"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05592-y"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2022.2081923"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2005.07.060"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00177a002"},{"volume-title":"Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health","year":"2021","author":"Substance Abuse and Mental Health Services Administration","key":"e_1_2_10_28_1"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(89)90025-7"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.887"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050185"},{"issue":"4","key":"e_1_2_10_32_1","first-page":"874","article-title":"Characterization of [3H]\u2010clocinnamox binding in mouse brain membranes","volume":"1","author":"Zernig G.","year":"1995","journal-title":"Analgesia"}],"container-title":["Journal of the Experimental Analysis of Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jeab.831","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jeab.831","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jeab.831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T01:55:39Z","timestamp":1692669339000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jeab.831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/jeab.831"],"URL":"https:\/\/doi.org\/10.1002\/jeab.831","archive":["Portico"],"relation":{},"ISSN":["0022-5002","1938-3711"],"issn-type":[{"type":"print","value":"0022-5002"},{"type":"electronic","value":"1938-3711"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"2022-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}